SOLIGENIX, INC. (SNGX)
$0.37-$0.01 (-1.68%) Today
Latest SNGX Insider Trades
Christopher J. Schaber - OfficerOpen-market purchase$20K
Christopher J. Schaber - OfficerSoligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
No Form 4 activity for SNGX in the last 90 days.
9 Form 4 filings on record, the earliest from Dec 13, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christopher J. Schaber - Officer | Open-market purchase | Common Stock | 15,132 | $1.32 | $20K | |
| Anthony Gregg Lapointe | Grant or award | Stock Option (Right to Buy) | 8,646 | $0.00 | - | |
| Robert J. Rubin | Grant or award | Stock Option (Right to Buy) | 8,646 | $0.00 | - | |
| Jerome B. Zeldis | Grant or award | Stock Option (Right to Buy) | 8,646 | $0.00 | - | |
| Diane L. Parks | Grant or award | Stock Option (Right to Buy) | 8,646 | $0.00 | - | |
| Jonathan L. Guarino - Officer | Grant or award | Option (Right to Buy) | 20,000 | $0.00 | - | |
| Richard Straube - Officer | Grant or award | Option (Right to Buy) | 12,000 | $0.00 | - | |
| Oreola Donini - Officer | Grant or award | Option (Right to Buy) | 20,000 | $0.00 | - | |
| Christopher J. Schaber - Officer | Grant or award | Option (Right to Buy) | 45,000 | $0.00 | - |
SOLIGENIX, INC. (SNGX) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-10-03. The full record for SNGX runs to 9 Form 4 filings, the earliest from 2024-12-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SNGX were filed in the last 90 days. 1 purchase is on record for this company.
No insider sales of SNGX were filed in the last 90 days.
This page tracks SNGX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SNGX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
